January Gerstoft - Infectious Diseases

Author Information

Jan Gerstoft is a distinguished researcher in the field of Infectious Diseases, affiliated with the Department of Infectious Diseases and Rheumatology at Copenhagen University Hospital, Rigshospitalet, located in Copenhagen, Denmark. His work primarily focuses on HIV and its associated complications, as well as responses to treatment for COVID-19.

Research Contributions

Jan Gerstoft has made significant contributions to the understanding of HIV and its effects on individuals, including the association of HIV with insulin resistance, aortic aneurysms, and type 2 diabetes mellitus. His research also explores the immune responses in HIV patients, such as the humoral response to COVID-19 vaccinations and the efficacy of monoclonal antibody therapies. Gerstoft's work extends to examining the risk factors for subarachnoid haemorrhages and aneurysms in people living with HIV, as well as investigating radiographic emphysema and electrocardiographic abnormalities in this population.

Aliases

Jan Gerstoft is known by several aliases, including J Gerstoft, J. Gerstoft, and January Gerstoft. These variations of his name appear in various publications and databases.

Publication and Citation Metrics

Metric	Value
Citation Count	19,535
h-index	68
Paper Count	538

Publications:

Insulin resistance in people living with HIV is associated with exposure to thymidine analogues and/or didanosine and prior immunodeficiency

DOI: 10.21203/rs.3.rs-1296618/v1

Year: 2022

Risk of subarachnoid haemorrhages and aneurysms in Danish People Living With HIV, a nationwide cohort study.

DOI: 10.1097/QAD.0000000000003260

Year: 2022

Epitope length variants balance protective immune responses and viral escape in HIV-1 infection.

DOI: 10.1016/j.celrep.2022.110449

Year: 2022

HIV infection is associated with thoracic and abdominal aortic aneurysms: a prospective matched cohort study.

DOI: 10.1093/eurheartj/ehab348

Year: 2021

HIV Infection Is Associated With Type 2 Diabetes Mellitus

DOI: 10.1097/QAI.0000000000002798

Year: 2021

LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

DOI: 10.1093/ofid/ofab466.1642

Year: 2021

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

DOI: 10.1016/S1473-3099(21)00751-9

Year: 2021

Independent Associations of Tumor Necrosis Factor-Alpha and Interleukin-1 Beta With Radiographic Emphysema in People Living With HIV

DOI: 10.3389/fimmu.2021.668113

Year: 2021

De novo electrocardiographic abnormalities in persons living with HIV

DOI: 10.1038/s41598-021-00290-x

Year: 2021

Humoral response to two doses of BNT162b2 vaccination in people with HIV

DOI: 10.1111/joim.13419

Year: 2021

What is the Future of Vaccinations?

What are the Symptoms of Cervical Cancer?

Which Infectious Diseases Commonly Cause Fatigue?

Can Surface Contamination Cause Infection?

What Guidelines Does the CDC Provide for Infectious Disease Prevention?

What Are the Challenges in Targeting Glycolysis?

What are Antifungals?

How Does Monogamy Affect the Spread of Infectious Diseases?

What is Chikungunya?

What Are Sexually Transmitted Infections (STIs)?

Partnered Content Networks

Relevant Topics